Background: Bloodborne hepatitis B virus (HBV) transmission from asymptomatic donors with acute HBV infections who have undetectable surface antigen of HBV (HBsAg), or from donors with chronic infections in whom serological markers were not detected, could cause residual infections leading to relevant transfusion-transmitted infections (RTTIs). HBV nucleic acid testing (NAT) can detect HBV DNA in the HBsAgnegative and total hepatitis B core antibody (anti-HBc)-negative window period of infection and in chronic cases.
Hepatitis B virus (HBV) is one of several viruses known to cause viral hepatitis. HBV infection leads to a wide range of liver diseases, such as acute hepatitis (including fulminant hepatic failure), chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC). 1 More than two billion people throughout the world have been infected with HBV, of whom more than 350 million are chronically infected carriers. After extraction of the fresh serum specimens from the participants, we conducted the following serological tests:
• HBs Ag testing (ARCHITECT anti-HBc II; Abbott Laboratories Inc.): a one-step immunoassay for the qualitative detection of the HBsAg in human serum and plasma using chemiluminescent microparticle immunoassay (CMIA) technology, with flexible assay protocols that are referred to as Chemiflex • Anti-HBc assay (ARCHITECT anti-HBs assay; Abbott Laboratories Inc.): a 2-step immunoassay for the qualitative detection of anti-HBc in human serum and plasma using CMIA technology • Hepatitis B surface antigen antibody assay (anti-HBs; ARCHITECT; Abbott Laboratories Inc.): a 2-step immunoassay, using CMIA technology, for the quantitative determination of anti-HBs in human serum and plasma
Individual NAT
NAT was performed, after extraction of fresh plasma specimens from study participants, by using COBAS Taq Screen MPX (all COBAS products by F. Hoffman-La Roche, Ltd.), a qualitative multiplex test that enables the screening and simultaneous detection of HBV DNA in individual plasma specimens from blood donors. This test uses a generic nucleic-acid preparation technique on the COBAS Ampliprep instrument. HBV DNA is amplified and detected using automated, real-time polymerase chain reaction (PCR) on the COBAS Taq Man Analyzer. All blood donors were tested for NAT.
Anti-HBs test was performed for all blood donors who tested anti-HBc positive/HBsAg negative. Individual plasma
Figure 1
Cumulative results of surface antigen of the hepatitis B virus (HBsAg) and total hepatitis B core antibody (anti-HBc) testing on blood donors. + indicates positive; −, negative.
specimens from blood donors were used for individual NAT testing. Individual NAT testing was done just. We confirmed the HBsAg-positive status (using NAT) of donors via PCR which was performed according to manufacturer specifications. We did not perform real-time quantitative PCR (rt-qPCR).
Statistical Analysis
Data were analyzed by using SPSS (Statistical Package for the Social Sciences) software, version 17.0.
Results
The cumulative results of HBsAg and anti-HBc testing on the 3014 blood donors in our cohort are depicted in Figure 1 . A total of 272 donors (9.0%) were tested for seroprevalence of HBV infection, of which 8 (0.26%) tested positive for HBsAg and 264 (8.8%) tested positive for anti-HBc and negative for HBsAg. Among the 264 donors who tested anti-HBc positive and HBsAg negative, the most frequent pattern was the association of anti-HBc with anti-HBs, at 78.4% (207/264; Figure 2 ).
All donated blood specimens were assayed for HBV-DNA using the HBV-NAT test, which is a commercial qualitative target-amplification method. Also, those specimens were validated for blood-donation screening (COBAS Taq Screen MPX test).
HBV-NAT testing showed reactivity in 75.0% (6/8) of subjects who tested HBsAg positive. Nonreactivity was revealed in 100% (264/264) of subjects who tested anti-HBc positive/HBsAg negative (with or without anti-HBs).
As shown in HBV-NAT testing was nonreactive in 100% (207/207) of subjects who tested anti-HBc positive/HBsAg negative who had anti-HBs. The testing was nonreactive in 100% (57/57) of those who tested anti-HBc positive/HBsAg negative and did not have anti-HBs ( Table 2) . Among 2742 donors with seronegativity (HBs Ag, anti-HBc, and anti-HBs), 1 specimen was reactive via HBV-NAT testing.
Discussion
The World Health Organization (WHO) has estimated that worldwide, there are still 360 million people who are chronically infected with HBV. 13 It has been estimated 14 that infections with HBV were responsible for approximately 59% of HCC cases in developing countries.
Screening of donated blood for transfusion-transmissible infections represents one of the most important strategies for blood-transfusion safety and availability. In the current study, we detected HBV DNA in 0.04% of the blood donors who tested HBsAg negative. This finding may indicate the significance of the HBV NAT technique in reducing the residual risk of transfusion-transmitted HBV infection among blood donors who test negative for anti-HBs. This finding may be explained by the fact that Saudi Arabia had achieved significant cultural and economic development during the past 2 decades. Also, the low frequency of HBV DNA in blood donors who test HBsAg negative blood donors may result from the presence of a national hepatitis B prevention program. We hope that our results may be useful to our colleagues in other countries as they seek new methods to strengthen the safety of their blood supply. LM
